Q1: 2026-05-11 Earnings Summary
EPS of -$0.74 misses by $0.41
|
Revenue of
$44.20M
(-7.59% Y/Y)
misses by $8.28M
Harrow, Inc. (HROW) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT
Company Participants
Michael Biega - Vice President of Investor Relations & Communications
Mark Baum - CEO, Chairman of the Board & Founder
Andrew Boll - President, CFO & Corporate Secretary
Patrick Sullivan - Chief Commercial Officer
Amir Shojaei - Chief Scientific Officer
Conference Call Participants
Timur Ivannikov - Cantor Fitzgerald & Co., Research Division
Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division
Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division
Thomas Shrader - BTIG, LLC, Research Division
Mayank Mamtani - B. Riley Securities, Inc., Research Division
Thomas Flaten - Lake Street Capital Markets, LLC, Research Division
Yi Chen - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, and welcome to Harrow's First Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the call over to Mike Biega, Vice President of Investor Relations and Communications for Harrow. Please go ahead.
Michael Biega
Vice President of Investor Relations & Communications
Thank you, operator. Good morning, and welcome to Harrow's first quarter 2026 earnings conference call. My name is Mike Biega, Vice President of Investor Relations and Communications, and I'm excited to be introducing today's call.
The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies and FDA approval of certain drug candidates in a timely manner or at all.
For
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。